[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]

August 2019 - April 2015




February 2019, Vol 5, No. 2, Pages 135-271

Original Investigation

Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study

Abstract Full Text
has audio
JAMA Oncol. 2019;5(2):155-163. doi:10.1001/jamaoncol.2018.5327

This secondary analysis of the Women’s Health Initiative randomized clinical trial and observational study cohort investigates the association between body fat and breast cancer risk in postmenopausal women with normal body mass index.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(2):164-170. doi:10.1001/jamaoncol.2018.5543

This randomized clinical trial examines whether patients treated with sunitinib before cytoreductive nephrectomy have better outcomes than patients immediately treated with cytoreductive nephrectomy and then given sunitinib.

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Abstract Full Text
free access
JAMA Oncol. 2019;5(2):173-180. doi:10.1001/jamaoncol.2018.4305

This study assesses whether plasma-based next-generation sequencing was associated with improved mutation detection and enhanced delivery of personalized therapy in a real-world clinical setting of patients with non–small cell lung cancer.

Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women

Abstract Full Text
JAMA Oncol. 2019;5(2):181-186. doi:10.1001/jamaoncol.2018.4270

This prospective cohort study evaluates the 5-year risk of cervical precancer following p16/ki-67 dual-stain triage of HPV-positive women.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

Abstract Full Text
JAMA Oncol. 2019;5(2):187-194. doi:10.1001/jamaoncol.2018.4514

This follow-up of a randomized phase 3 trial compares the 3-year survival with nivolumab vs that with dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(2):195-203. doi:10.1001/jamaoncol.2018.4628

This phase 2 randomized clinical trial compare the efficacy and toxicity profiles of durvalumab monotherapy and tremelimumab monotherapy against a combination of both in patients with recurrent or metastatic head and neck squamous cell carcinoma with low or no expression of programmed death ligand 1.

Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study

Abstract Full Text
open access
JAMA Oncol. 2019;5(2):204-212. doi:10.1001/jamaoncol.2018.4616

This prospective study examines the diagnostic accuracy of a multigene genomic classifier test for diagnosis of benign disease or cancer in thyroid nodules with indeterminate cytology.

Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality

Abstract Full Text
has audio
JAMA Oncol. 2019;5(2):213-220. doi:10.1001/jamaoncol.2018.4836

This cohort study investigates whether treatment of Gleason score 9-10 prostate cancer with radical prostatectomy, adjuvant external beam radiotherapy, and androgen deprivation therapy (termed MaxRP) vs external beam radiotherapy, brachytherapy, and androgen deprivation therapy (termed MaxRT) was associated with prostate cancer–specific mortality and all-cause mortality risk.

Assessment of Risk of Xerostomia After Whole-Brain Radiation Therapy and Association With Parotid Dose

Abstract Full Text
JAMA Oncol. 2019;5(2):221-228. doi:10.1001/jamaoncol.2018.4951

This cohort study investigates the association between radiation doses in the parotid glands and self-reported xerostomia among adults treated with whole-brain radiation therapy.

Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients

Abstract Full Text
JAMA Oncol. 2019;5(2):229-235. doi:10.1001/jamaoncol.2018.4934

This cohort study examines patient data in the European Society for Blood and Marrow Transplantation Registry for causes of death, risk factors, and overall survival rates among patients who received a second cancer diagnosis after being treated with stem cell transplant.

Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2019;5(2):236-242. doi:10.1001/jamaoncol.2018.5070

This Markov model study assesses the cost-effectiveness of capecitabine and bevacizumab maintenance therapy after induction chemotherapy for treatment of metastatic colorectal cancer.

Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

Abstract Full Text
open access online only
JAMA Oncol. 2019;5(2):e184475. doi:10.1001/jamaoncol.2018.4475

This phase 1b clinical trial evaluates the dose response and safety of alpelisib plus fulvestrant treatment in women with advanced breast cancer.

Brief Report

Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(2):243-247. doi:10.1001/jamaoncol.2018.4610

This exploratory secondary analysis of a randomized clinical trial evaluated local control of brain metastases among patients treated with stereotactic radiosurgery vs surgical resection in the European Organization for the Research and Treatment of Cancer 22952-26001 phase 3 trial.

Research Letter

Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms

Abstract Full Text
JAMA Oncol. 2019;5(2):265-267. doi:10.1001/jamaoncol.2018.6286

This study uses clinical sequencing data to examine the association between JAK2-V617F detected by solid tumor sequencing and mutations in the tumor, clonal hematopoiesis of indeterminate potential, or myeloproliferative neoplasms.

Assessment of Radiotherapy-Associated Angiosarcoma After Breast Cancer Treatment in a Dutch Population-Based Study

Abstract Full Text
JAMA Oncol. 2019;5(2):267-269. doi:10.1001/jamaoncol.2018.6643

This population-based study describes the incidence, latency period, and outcomes of radiotherapy-associated angiosarcoma among patients with breast cancer from the Netherlands Cancer Registry.


Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(2):254-260. doi:10.1001/jamaoncol.2018.4490

This narrative review discusses current understanding of alveolar soft-part sarcomas with a focus on new findings and treatments.

JAMA Network Insights

Treatment of Metastatic Prostate Cancer in 2018

Abstract Full Text
JAMA Oncol. 2019;5(2):263-264. doi:10.1001/jamaoncol.2018.5621

In this article the authors review the shift toward earlier use of therapeutic treatments in the course of advanced prostate cancer

JAMA Oncology Clinical Challenge

Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non–Small Cell Lung Cancer

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(2):261-262. doi:10.1001/jamaoncol.2018.4485

An HIV-positive man in his 30s being treated with pembrolizumab for metastatic programmed cell death ligand 1–positive squamous non–small cell lung cancer presents with pruritic, mildly painful, hyperpigmented papules and plaques on both feet. What is your diagnosis?


Cyclin-Dependent Kinase Inhibitor–Associated Thromboembolism

Abstract Full Text
JAMA Oncol. 2019;5(2):141-142. doi:10.1001/jamaoncol.2018.5529

This Viewpoint analyzes data on the thrombotic risk associated with cyclin-dependent kinase inhibitors and notes the need for additional research on the thrombotic risk of these drugs, the influence of combined drug therapy on thrombotic risk, and patient selection.

Is Precision Medicine an Oxymoron?

Abstract Full Text
JAMA Oncol. 2019;5(2):142-143. doi:10.1001/jamaoncol.2018.5099

This Viewpoint discusses the initials results of the NCI-MATCH trial, a phase 2 study that seeks to determine whether targeted therapies for specific gene mutations will lead to objective responses agnostic to the primary cancer type.

Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer—The Forgotten Dance Partner?

Abstract Full Text
JAMA Oncol. 2019;5(2):144-145. doi:10.1001/jamaoncol.2018.5191

This Viewpoint uses results of randomized clinical trials to explore whether the use of abiraterone acetate plus prednisone is a cost-effective and appropriate treatment option for patients with nonmetastatic castration-resistant prostate cancer.


Plasma vs Tissue Next-Generation Sequencing in Non–Small Cell Lung Cancer—Either, Both, or Neither?

Abstract Full Text
JAMA Oncol. 2019;5(2):148-149. doi:10.1001/jamaoncol.2018.4304

Normal Weight Adiposity and Postmenopausal Breast Cancer Risk

Abstract Full Text
JAMA Oncol. 2019;5(2):150-151. doi:10.1001/jamaoncol.2018.5162
Invited Commentary

Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It’s Cut Out to Be

Abstract Full Text
JAMA Oncol. 2019;5(2):171-172. doi:10.1001/jamaoncol.2018.5503
Cancer Care Chronicles

Inappropriate Celebration in the Presence of Patients With Poor Prognosis—The Cancer Center Victory Bell

Abstract Full Text
JAMA Oncol. 2019;5(2):146-147. doi:10.1001/jamaoncol.2018.5647

This article examines the tradition of bell ringing as a method of celebrating the completion of cancer treatment.

Comment & Response

Inappropriate Grading of Adverse Events in Cancer Clinical Trials

Abstract Full Text
JAMA Oncol. 2019;5(2):269. doi:10.1001/jamaoncol.2018.5849

Inappropriate Grading of Adverse Events in Cancer Clinical Trials—Reply

Abstract Full Text
JAMA Oncol. 2019;5(2):269-270. doi:10.1001/jamaoncol.2018.5871

Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer

Abstract Full Text
JAMA Oncol. 2019;5(2):270. doi:10.1001/jamaoncol.2018.5857

Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer—Reply

Abstract Full Text
JAMA Oncol. 2019;5(2):270-271. doi:10.1001/jamaoncol.2018.5874

Incorrect Treatment Group in Results and Error in Legend of Figure 2

Abstract Full Text
free access
JAMA Oncol. 2019;5(2):271. doi:10.1001/jamaoncol.2018.6113

Typographical Errors in Table 2 and Text

Abstract Full Text
free access
JAMA Oncol. 2019;5(2):271. doi:10.1001/jamaoncol.2018.6413

Error in Author Affiliation

Abstract Full Text
free access
JAMA Oncol. 2019;5(2):271. doi:10.1001/jamaoncol.2019.0117
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2019;5(2):138. doi:10.1001/jamaoncol.2018.4738
In This Issue of JAMA Oncology


Abstract Full Text
free access
JAMA Oncol. 2019;5(2):135. doi:10.1001/jamaoncol.2018.4737